

**BIOLIDICS LIMITED**  
(Company Registration Number 200913076M)  
(Incorporated in the Republic of Singapore)

**GRANT OF SHARE AWARDS PURSUANT TO THE BIOLIDICS PERFORMANCE SHARE PLAN  
– AMENDMENT OF VESTING PERIOD**

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**") refers to the Company's announcement dated 28 February 2023 in relation to the grant of share awards (the "**2023 Awards**") to certain employees and a director of the Company pursuant to the Biolidics Performance Share Plan.

The Board wishes to announce that the remuneration committee of the Company has, on 31 July 2023, amended the vesting period of certain of the 2023 Awards, details of which are as follows:

<b>Number of 2023 Awards granted</b>	<b>Original vesting period</b>	<b>New vesting period</b>
Up to 21,079,800	Within 2 months from 1 March 2023, subject to the achievement of predetermined performance targets	Within 2 months from 1 January 2024, subject to the achievement of predetermined performance targets
Up to 21,079,800	Within 4 months from 1 January 2024, subject to the achievement of predetermined performance targets	Within 2 months from 1 January 2025, subject to the achievement of predetermined performance targets

Save as disclosed above, there were no other changes made to the terms and conditions of the 2023 Awards that were granted on 28 February 2023, including the predetermined performance targets that were set for the vesting of the 2023 Awards.

Following the above-mentioned changes, the details of the outstanding 2023 Awards as at the date of this announcement, which excludes the 28,258,700 2023 Awards that had vested on the date of the grant, are as follows:

(a)	Date of grant	28 February 2023		
(b)	Exercise price of the outstanding 2023 Awards granted	Not applicable		
(c)	Aggregate number of issued ordinary shares in the capital of the Company (" <b>Shares</b> ") comprised in the outstanding 2023 Awards granted	Up to 42,159,600 Shares subject to the vesting of the outstanding 2023 Awards		
(d)	Market price (last done price) of the Shares on the date of grant	S\$0.016		
(e)	Number of Shares which are the subject of the outstanding 2023 Awards granted to directors and controlling shareholders (and each of their associates) of the Company	<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"><b><u>Name of participant</u></b> Song Tang Yih, the Executive Director and Chief Executive Officer of the Company</td> <td style="width: 50%; border: none;"><b><u>Number of Shares</u></b> Up to 22,293,600 Shares subject to the vesting of the outstanding 2023 Awards</td> </tr> </table>	<b><u>Name of participant</u></b> Song Tang Yih, the Executive Director and Chief Executive Officer of the Company	<b><u>Number of Shares</u></b> Up to 22,293,600 Shares subject to the vesting of the outstanding 2023 Awards
<b><u>Name of participant</u></b> Song Tang Yih, the Executive Director and Chief Executive Officer of the Company	<b><u>Number of Shares</u></b> Up to 22,293,600 Shares subject to the vesting of the outstanding 2023 Awards			

(f)	Vesting period of the outstanding 2023 Awards	<p>Up to 21,079,800 Shares, within 2 months from 1 January 2024, subject to the achievement of predetermined performance targets.</p> <p>Up to 21,079,800 Shares, within 2 months from 1 January 2025, subject to the achievement of predetermined performance targets.</p>
-----	-----------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**BY ORDER OF THE BOARD**

**Ian David Brown**  
**Independent Director**  
**31 July 2023**

*This announcement has been prepared by Biolidics Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) and has been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “**Sponsor**”), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”). This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Lim Hoon Khat, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*